List of investigational sex-hormonal agents

From WikiProjectMed
Jump to navigation Jump to search

This is a list of investigational sex-hormonal agents, or sex-hormonal agents that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Androgenics

Androgen receptor agonists

Selective androgen receptor modulators

Androgen receptor antagonists

Atypical androgen receptor antagonists

Androgen synthesis inhibitors

Estrogenics

Estrogen receptor agonists

Selective estrogen receptor modulators

  • Acolbifene (EM-652, SCH-57068) – selective estrogen receptor modulator for breast cancer [23]
  • Afimoxifene (4-hydroxytamoxifen; 4-OHT; TamoGel) – selective estrogen receptor modulator for topical treatment of breast cancer and hyperplasia [24]
  • Amcenestrant (SAR-439859; SERD '859) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer [25]
  • Camizestrant (AZ14066724, AZD-9833) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer [26]
  • Endoxifen (4-hydroxy-N-desmethyltamoxifen) – selective estrogen receptor modulator for breast cancer [27]
  • Giredestrant (GDC-9545; RG-6171) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer [28]
  • Imlunestrant (LY-3484356) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer and endometrial cancer [29]
  • Rintodestrant (G1T-48) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer [30]

Estrogen receptor antagonists

Estrogen synthesis inhibitors

Progestogenics

Progesterone receptor agonists

Selective progesterone receptor modulators

Progesterone receptor antagonists

GnRH/gonadotropins

Kisspeptin receptor agonists

Neurokinin/tachykinin receptor antagonists

Mixed/combinations

Androgen and progesterone receptor modulators

Androgen and estrogen receptor modulators

Androgen, estrogen, and progesterone receptor modulators

See also

References

  1. ^ a b "R&D Research". www.evestra.com. Archived from the original on 2017-09-29.
  2. ^ a b Ahmed G, Elger W, Meece F, Nair HB, Schneider B, Wyrwa R, Nickisch K (October 2017). "A prodrug design for improved oral absorption and reduced hepatic interaction". Bioorg. Med. Chem. 25 (20): 5569–5575. doi:10.1016/j.bmc.2017.08.027. PMID 28886996.
  3. ^ Zeng S, Huang W, Zheng X, Liyan C, Zhang Z, Wang J, Shen Z (January 2021). "Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges". Eur J Med Chem. 210: 112981. doi:10.1016/j.ejmech.2020.112981. PMID 33160761. S2CID 226287993.
  4. ^ Tong, Youzhi; Chen, Chunyun; Wu, Juan; Yang, Jiangtao; Zhang, Huihui; Wu, Xiaojun; Duan, Yanmei; Gao, Wei; Qian, Weidong; Niu, Xiaoxia; Mi, Lili; Guo, Chuangxing (2014). "Abstract 614: Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor". Cancer Research. 74 (19 Supplement): 614. doi:10.1158/1538-7445.AM2014-614. ISSN 0008-5472.
  5. ^ "Pyrilutamide - Suzhou Kintor Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
  6. ^ Renz S, Chinnery F, Stuart B, Day L, Muller I, Soulsby I, Nuttall J, Thomas K, Thomas KS, Sach T, Stanton L, Ridd MJ, Francis N, Little P, Eminton Z, Griffiths G, Layton AM, Santer M (August 2021). "Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women". BMJ Open. 11 (8): e053876. doi:10.1136/bmjopen-2021-053876. PMC 8395279. PMID 34446504.
  7. ^ Poinas A, Lemoigne M, Le Naour S, Nguyen JM, Schirr-Bonnans S, Riche VP, Vrignaud F, Machet L, Claudel JP, Leccia MT, Hainaut E, Beneton N, Dert C, Boisrobert A, Flet L, Chiffoleau A, Corvec S, Khammari A, Dréno B (June 2020). "FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial". Trials. 21 (1): 571. doi:10.1186/s13063-020-04432-w. PMC 7318446. PMID 32586344.
  8. ^ Elger W, Wyrwa R, Ahmed G, Meece F, Nair HB, Santhamma B, Killeen Z, Schneider B, Meister R, Schubert H, Nickisch K (January 2017). "Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions". J. Steroid Biochem. Mol. Biol. 165 (Pt B): 305–311. doi:10.1016/j.jsbmb.2016.07.008. PMID 27449818. S2CID 26650319.
  9. ^ Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G (2016). "Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)". J. Med. Chem. 59 (17): 8134–40. doi:10.1021/acs.jmedchem.6b00753. PMC 5499704. PMID 27529700.
  10. ^ Wang, G; Liu, J; Zheng, S; Miele, L; Wiese, T; Zhong, Q; Guo, S (2017). "Abstract P2-08-11: An orally bioavailable selective estrogen receptor downregulator". Cancer Research. 77 (4 Supplement): P2-08-11–P2-08-11. doi:10.1158/1538-7445.SABCS16-P2-08-11. ISSN 0008-5472.
  11. ^ "Hydroxyprogesterone - Lipocine - AdisInsight".
  12. ^ "Second potential male birth control pill passes human safety tests".
  13. ^ "Dimethandrolone undecanoate shows promise as a male birth control pill".

External links